文献速递中医内科针灸推拿中药与中成药合理使用

壮医药线点灸治疗寻常型银屑病:多中心随机平行对照试验

Treatment of Psoriasis Vulgaris with Medicated Thread Moxibustion of Zhuang Medicine: A Multicenter Randomized, Parallel Controlled Trial.
PubMed 文献 · Chin J Integr Med · 2021-12-12

本研究为多中心随机平行对照试验,纳入241例寻常型银屑病门诊患者,对照组(120例)单用西药,治疗组(121例)在西药基础上加壮医药线点灸,每2天1次,连续干预30天。意向性分析纳入236例,每组118例。结果显示治疗组在PASI评分、瘙痒评分、DLQI、HAMA及PASI 50/75应答率上均优于对照组,随访期改善更明显,两组均未见明显不良反应。

要点

  • 壮医药线点灸联合西药可显著降低寻常型银屑病PASI评分。
  • 联合治疗在瘙痒、生活质量及焦虑改善方面优于单用西药。
  • PASI 50和75应答率治疗组显著高于对照组,未见明显不良反应。

核心结论

  • 壮医药线点灸联合西药治疗寻常型银屑病疗效优于单用西药,且无明显不良反应。

研究设计与样本

  • 多中心、随机、平行对照临床试验,2015年6月至2018年5月纳入241例寻常型银屑病门诊患者,中央区组随机分为对照组120例和治疗组121例。
  • 对照组单用西药(匹多莫德分散片、复合维生素B片、复方鱼肝油氧化锌软膏),治疗组加壮医药线点灸每2天1次,两组连续干预30天,随访30天。
  • 意向性分析纳入236例,每组118例,脱落5例。

主要发现

  • 第30天和第60天两组PASI评分均较基线显著降低(P<0.01),治疗组PASI评分下降幅度大于对照组(P<0.01)。
  • 治疗后两组瘙痒评分、DLQI、HAMA评分均下降,治疗组疗效更优(P<0.01)。
  • 治疗组PASI 50和75应答率分别为81.4%(96/118)和43.2%(51/118),显著高于对照组的41.5%(49/118)和11.0%(13/118)(P<0.05)。
  • 随访期治疗组PASI、瘙痒评分、DLQI、HAMA改善均显著大于对照组(P<0.01),PASI 50和75应答率均显著高于对照组(均P<0.05)。
  • 两组均未见明显不良反应。

关键数值与推荐

  • 主要结局为PASI评分,次要结局包括瘙痒评分、DLQI、HAMA及PASI应答率。
  • PASI 50应答率:治疗组81.4%(96/118) vs 对照组41.5%(49/118),P<0.05。
  • PASI 75应答率:治疗组43.2%(51/118) vs 对照组11.0%(13/118),P<0.05。

临床怎么用

  • 对寻常型银屑病患者,可在西药治疗基础上联合壮医药线点灸,每2天1次,连续30天。
  • 联合治疗可改善皮损严重程度、瘙痒、生活质量及焦虑情绪,且安全性较好。

局限性

  • 脱落5例,意向性分析纳入236例,每组118例。
  • 随访时间为治疗后30天,长期疗效未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the efficacy and safety of Zhuang medicine medicated thread moxibustion (ZMTM) on psoriasis vulgaris. METHODS: A multicenter, randomized, parallel controlled clinical trial was designed. A total of 241 outpatients with psoriasis vulgaris were randomly divided into a control group (120 cases) and a treatment group (121 cases) using a central block randomization from June 2015 to May 2018. The control group was treated with Western medicines alone including pidotimod dispersible tablets, vitamin B compound tablets, and compound cod liver oil-zinc oxide ointment. The treatment group was treated with ZMTM every 2 days combined with Western medicines. The two groups received continuous intervention for 30 days. The primary outcome was Psoriasis Area and Severity Index (PASI), and the secondary outcomes included Itch Rating Scale, Dermatology Quality of Life Index (DLQI), Hamilton Anxiety Rating Scale (HAMA), as well as PASI response rate. Meanwhile, adverse events were evaluated during the whole clinical trial. Follow-up was carried out 30 days after treatment. RESULTS: There were 5 cases of shedding in this trial. In intention-to-treat analysis, 236 cases were included and each group contained 118 cases. On the 30th and 60th days, PASI scores of patients in each group were significantly lower than that at baseline (P<0.01) and the PASI score reduction of the treatment group was greater than that of the control group (P<0.01). Itch Rating Scale, DLQI, and HAMA scale were decreased in both groups after treatment, and the treatment group showed a better therapeutic effect (P<0.01). The response rates of PASI 50 and 75 were significantly higher than those in the control group [81.4% (96/118), 43.2% (51/118) vs. 41.5% (49/118), 11.0% (13/118), respectively, P<0.05]. During follow-up, the improvements in scores of PASI, Itch Rating Scale, DLQI, and HAMA of the treatment group were significantly greater than those of the control group (P<0.01). The response rates of PASI 50 and 75 in the treatment group were significantly higher than those in the control group, respectively (both P<0.05). No obvious adverse reaction was found in either group. CONCLUSION: ZMTM combined with Western medicines showed a better therapeutic effect in the treatment of psoriasis vulgaris without obvious adverse reaction. (Trial Registration No. ChiCTR-IOR-16008159).

来源:Chin J Integr Med,查看原文。版权归原作者所有。

引用

  1. Pang YZ, Tang J, Zhang QH, et al. Treatment of Psoriasis Vulgaris with Medicated Thread Moxibustion of Zhuang Medicine: A Multicenter Randomized, Parallel Controlled Trial. Chin J Integr Med. 2021. PMID: 34897593. doi:10.1007/s11655-021-3489-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。